PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

Summary

This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naïve subjects with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC).

Timeline

Start

2025-04-14

Primary completion

2026-09

Completion

2028-06

Drugs

Indications